Why the study?
Treatment approaches vary considerably and a consensus has yet to be reached on the most efficacious antiarrhythmic drug for infantile-onset SVT.
Do antiarrhythmic drugs improve management of supraventricular tachycardia in infants under one year old?
Do antiarrhythmic drugs improve management of supraventricular tachycardia in infants under one year old?
Answers are grounded in this paper and cite their sources.
This systematic review evaluates the current evidence on antiarrhythmic drugs for managing SVT in infants under one year old, an area where consensus on the most efficacious drug is currently lacking.
Supraventricular tachycardia (SVT) is the most prevalent arrhythmia observed in infants, impacting individuals with or without congenital cardiac dysfunction. Infantile-onset SVT typically manifests within the initial one to two months of life. A variety of anti-arrhythmic medications are employed to treat SVT in infants during their first year of life. Nevertheless, a consensus has yet to be reached on the most efficacious drug, and treatment approaches continue to vary considerably As SVT remains a frequent problem around the world, with different management approaches and no obvious optimal option, we conducted a systematic review of the new update of antiarrhythmic drugs for managing SVT in infants under one year old.
No takes yet. Share an insight, caveat, or question.
Azad Mojahedi (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: